PT  - JOURNAL ARTICLE
AU  - TAIGO KATO
AU  - AKIRA NAGAHARA
AU  - NORIHIKO KAWAMURA
AU  - WATARU NAKATA
AU  - TETSUJI SODA
AU  - KYOSUKE MATSUZAKI
AU  - KOJI HATANO
AU  - ATSUNARI KAWASHIMA
AU  - TAKESHI UJIKE
AU  - RYOICHI IMAMURA
AU  - KENSAKU NISHIMURA
AU  - SHINGO TAKADA
AU  - MASAO TSUJIHATA
AU  - SEIJI YAMAGUCHI
AU  - TETSUYA TAKAO
AU  - YASUTOMO NAKAI
AU  - MASASHI NAKAYAMA
AU  - NORIO NONOMURA
AU  - MOTOHIDE UEMURA
TI  - Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
AID  - 10.21873/anticanres.15398
DP  - 2021 Nov 01
TA  - Anticancer Research
PG  - 5811--5816
VI  - 41
IP  - 11
4099  - http://ar.iiarjournals.org/content/41/11/5811.short
4100  - http://ar.iiarjournals.org/content/41/11/5811.full
SO  - Anticancer Res2021 Nov 01; 41
AB  - Background/Aim: Immune checkpoint inhibitors (ICIs) have demonstrated a survival benefit for patients with cancer. However, the clinical outcomes of subsequent tyrosine kinase inhibitors (TKIs) after ICI failure in patients with metastatic renal cell carcinoma (mRCC) remain unclear. Patients and Methods: We retrospectively examined 38 patients with mRCC who started TKIs immediately after nivolumab with (combination group) or without ipilimumab (nivolumab group) between September 2016 and July 2019. Results: Of the 38 patients, 16 and 11 achieved partial response and stable disease, respectively, resulting in a 42.1% objective response rate and 71.1% disease control rate. The median progression-free survival (PFS) from TKI initiation was 8.8 and 12.9 months in the nivolumab and combination groups, respectively. PFS and overall survival were significantly longer in patients with long-term responses to previous ICI treatment (p=0.0152 and p=0.0155, respectively). Conclusion: TKIs demonstrate adequate anti-tumour activity after treatment with ICIs in real-world settings.